Mihaela Druta, MD
Medical Oncology · Tampa, FLNPI 1073707170
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.7%), speaking fees and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Deciphera Pharmaceuticals Inc. at 31.5% of the total. Reporting peaked in 2019 at $20,211 and has fallen 53.0% since, to $9,497 in 2025.
Across 80 payments — averaging $842.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$21K
- Daiichi Sankyo Inc.$20K
- Trillium Therapeutics USA, LLC$6K
- Adaptimmune LLC$5K
- EMD Serono, Inc.$4K
- Aadi Bioscience, Inc.$3K
- plus $8K from 10 others
Across 1,140 payments — averaging $4882.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$3.3M
- Trillium Therapeutics USA, LLC$908K
- PTC Therapeutics, Inc.$442K
- GSK$308K
- Pfizer$239K
- Chugai Pharmaceutical Co., Ltd.$218K
- plus $198K from 4 others
What the payments were for
- Consulting fees$36,85855%
- Speaking & faculty fees$19,13428%
- Travel & lodging$3,2775%
- Food & beverage$2,7694%
- Education$5,4008%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 20 | $21,261 |
| Daiichi Sankyo Inc. | 33 | $19,774 |
| Trillium Therapeutics USA, LLC | 6 | $6,048 |
| Adaptimmune LLC | 1 | $5,400 |
| EMD Serono, Inc. | 1 | $3,800 |
| Aadi Bioscience, Inc. | 8 | $3,435 |
| Eisai Inc. | 2 | $3,250 |
| Pfizer | 1 | $1,395 |
| Blueprint Medicines Corporation | 1 | $980 |
| Bayer | 1 | $900 |
| Boehringer Ingelheim | 1 | $740 |
| Ipsen Biopharmaceuticals, Inc | 1 | $141 |
| Johnson & Johnson | 1 | $126 |
| Novartis | 1 | $125 |
| Legend Biotech USA Inc. | 1 | $45 |
| Acera Surgical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,438 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sunitinib Malate | 12 | $129,984 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.